Cardiovascular Clinical Research Since 1997
We created Tracescribe Research to close the gap between expert cardiology insight and large-trial execution. Our physician-scientists and biostatisticians stay embedded through the full lifecycle, designing endpoint strategy early and delivering submission-ready outputs through a specialized global CV site network.
Scientific leadership reviews every inquiry and responds within 48 hours.
Leadership
Our founders do not operate as ceremonial advisors. They remain embedded in scientific strategy, medical oversight, and endpoint quality from first draft through final submission.
Former Chief of Cardiology at a leading academic center. Principal Investigator on landmark heart failure programs and contributor to early comprehensive practice guidance.
"We built Tracescribe Research after watching generalist CRO structures fail cardiovascular science."
Cardiologist and imaging specialist with leadership across pivotal PET and nuclear cardiology initiatives, now directing Tracescribe's cardiovascular core laboratory.
"When regulators ask who read your images, the answer should remove uncertainty, not create it."
Brings 25+ years of drug development and global clinical operations leadership, translating deep cardiovascular science into predictable program execution.
Oversees medical monitoring, safety surveillance, adjudication strategy, and cross-program risk review across active Tracescribe studies.
The Execution Gap
Most setbacks are operational, not scientific: rotating teams, late-stage data rescue, and budgets that fracture under pressure. We designed Tracescribe to remove those failure modes.
01
The experts who win the work are replaced after kickoff, forcing sponsors to retrain new teams while timelines slip.
02
Biostatistics is often brought in near database lock, requiring costly reconstruction instead of intentional design.
03
Conservative bids become reactive change orders, eroding confidence and pushing regulatory timelines.
Operating Commitments
These are not positioning statements. They are operating constraints we design around and report against.
The scientific and statistical leads who shape your analysis plan are the same experts who deliver topline interpretation.
Current continuity benchmark: 94%
Biostatistics and data management are engaged before first CRF build, with estimands, CDISC standards, and adaptive logic aligned upfront.
Change-order triggers are defined before signature, with transparent assumptions designed to minimize surprises at lock.
Services
One specialized team from strategy to submission, integrating clinical operations, data quality, analytics, and safety.
Core Lab Spotlight
Tracescribe's blinded independent central reads are led by specialists with direct experience in pivotal cardiac imaging programs. The standard is simple: the reader profile must withstand regulator-level scrutiny.
Data Strategy Timeline
Database lock is not a rescue event. It is the outcome of decisions made before enrollment begins.
Biostatistics and data management engage at concept stage.
Standards and structures are locked before first patient in.
Execution starts on pre-validated operational and data rails.
Programmatic checks run from first data, not near lock.
A quality confirmation milestone, not an emergency sprint.
Submission-ready datasets and analyses delivered with traceability.
Global Reach
This is a focused network, not a general-purpose index. Regional consistency is managed through standardized protocols and active geographic irregularity monitoring.
1,200+
800+
350+
150+
Quality System
Our quality management system aligns with ICH E6(R2) risk-based principles, CAPA governance, ALCOA+ data integrity standards, and continuous inspection readiness. At Tracescribe, quality is not a department; it is the operating system.
Contact
Your inquiry is reviewed by scientific leadership directly. No routing through generic intake. Share your program goals, current phase, and support needs, and we will assess fit within 48 hours.